🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11376247

Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy

The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11377428

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc. · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11377444

Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors

Medshine Discovery Inc. · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11377469

CD73 inhibitors

ORIC PHARMACEUTICALS, INC. · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370803

Heteroaryl plasma kallikrein inhibitors

Takeda Pharmaceutical Company Limited · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370774

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement

BioCryst Pharmaceuticals, Inc. · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370786

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370798

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370765

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc. · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370764

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc. · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370769

TRPC5 inhibitors and methods of using same

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11365195

Atypical inhibitors of monoamine transporters; method of making; and use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11365189

Heterocyclic inhibitors of tyrosine kinase

The Board of Regents of the University of Texas System · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11364300

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

Revolution Medicines, Inc. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11364211

Methods for selecting phosphatase selective and non-selective phosphatase inhibitors

United Kingdom Research and Innovation · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11364235

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting r

Actinium Phamaceuticals, Inc. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11364227

Sphingosine kinase 2 inhibitor for treating coronavirus infection

RedHill Biopharma Ltd. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11358932

N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosyl

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11358947

Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of

The Regents of the University of California · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11359246

Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11357817

Immunoproteasome inhibitor

The Regents of the University of California · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11357759

Composition including ADAM9 inhibitor and the use thereof

China Medical University · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352356

Inhibitors of plasma kallikrein and uses thereof

Takeda Pharmaceutical Company Limited · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352360

TGF-beta inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted